Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

Future Oncology

Volumn 6, Issue 7, 2010, Pages 1073-1084

  Navari, Rudolph M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Harper Cancer Institute   (United States)

Author keywords

antiemetic; chemotherapy induced nausea and vomiting; palonosetron; serotonin receptor antagonist

Indexed keywords

ALCOHOL; ANALGESIC AGENT; ANTHRACYCLINE; ANTIEMETIC AGENT; APREPITANT; AZASETRON; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANISETRON; METOCLOPRAMIDE; MITOMYCIN C; MITOXANTRONE; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; RAMOSETRON; SEROTONIN 3 RECEPTOR; TROPISETRON; UNINDEXED DRUG; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN AGONIST;

BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HUMAN; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; VOMITING; CHEMICALLY INDUCED; CHEMISTRY; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK FACTOR; SAFETY; STANDARDS;

ANTIEMETICS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; ISOQUINOLINES; NAUSEA; NEOPLASMS; QUINUCLIDINES; RISK FACTORS; SAFETY; SEROTONIN AGONISTS; VOMITING; SEROTONIN RECEPTOR AGONISTS;

EID: 77954676446     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.74     Document Type: Review

References (50)

1. Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R: Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supp. Cancer Therapy 2, 181-187 (2005).
2. Cohen L, de Moor CA, Eisenberg P, et al.: Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support. Care Cancer 15(5), 497-503 (2005).
3. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch JR: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97, 2880-2886 (2003).
4. Grunberg SM, Deuson R, Mavros P, et al.: Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus reality. Cancer 100, 2261-2268 (2004).
5. Grunberg SM, Osoba D, Hesketh PJ, et al.: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support. Care Cancer 13, 80-84 (2005).
6. Navari RM, Province PS: Emerging drugs for chemotherapy-induced emesis. Expert Opin. Emerging Drugs 11, 137-151 (2006).
7. Navari RM: Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69(5), 515-533 (2009).
8. Roila F, Warr D, Clark-Snow R, et al.: Delayed emesis: moderately emetogenic chemotherapy. Support. Care Cancer 13(2), 104-108 (2005). (Pubitemid 40558165)
9. Geling O, Eichler H: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. 23, 1289-1294 (2005).
10. Hickok JT, Roscoe JA, Morrow GR, et al.: 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol. 6, 765-772 (2005).
11. Hesketh PJ: New treatment options for chemotherapy-induced nausea and vomiting. Support. Care Cancer 12, 550-554 (2004).
12. Navari RM: Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J. Support. Oncol. 1, 89-103 (2003).
13. Kris MG, Hesketh PJ, Somerfield MR, et al.; American Society of Clinical Oncology: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol. 24(18), 2932-2947 (2006).
14. Simpson K, Spencer CM, McClellan KJ: Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 59, 1297-1315 (2000).
15. Kimura E, Niimi E, Watanabe A, et al.: Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 23, 477-481 (1996).
16. Taguchi T, Tsukamoto F, Watanabe T, et al.: Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho. 26, 1163-1170 (1999).
17. Navari RM, Koeller JM: Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann. Pharmacother. 37, 1276-1286 (2003).
18. WHO Drug Information. 20. No.3 (2006).
19. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al.: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer 98, 2473-2482 (2003).
20. Gralla R, Lichinitser M, Van Der Vegt S, et al.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14, 1570-1577 (2003).
21. Eisenberg P, MacKintosh FR, Ritch P, et al.: Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol. 15, 330-337 (2004).
22. Aapro MS, Grunberg SM, Manikhas GM, et al.: A Phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 17, 1441-1449 (2006).
23. Saito M, Aogi K, Sekine I, et al.: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative Phase III trial. Lancet Oncol. 10, 115-124 (2009).
24. DeJonghe BC, Horn CC: Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am J. Physiol. Regul. Integr. Comp. Physiol. 294(4), R902-R911 (2009).
25. Aloxi® (palonosetron HCl) injection, prescribing information. Eisai, Inc., Woodcliffe Lake, NJ, USA (2008).
26. Cantoreggi S, Parisi S, Van Laar E, et al.: Palonosetron, a new 5-HT3 antagonist does not alter anti-tumor efficacy of various chemotherapeutics in tumor bearing mice. Clin. Cancer Res. 9, 6254S (2003) (Abstract).
27. Decker GM, DeMeyer ES, Kisko DL: Measuring the maintenance of daily life activities using the Fuctional Living Index- Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J. Support. Oncol. 4, 35-41 (2006).
28. Cartmell AD, Ferguson S, Yanagihara R, et al.: Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist. Proc. Am. Soc. Clin. Oncol. 756 (2003) (Abstract 3041).
29. Yu Z, Liu W, Wang L, et al.: The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a Phase II, multicenter, randomized, comparative clinical trial. Support. Care Cancer 17(1), 99-102 (2009).
30. Rojas C, Stathis M, Thomas AG, et al.: Palonosetron exhibits unique molecular interactions with the 5HT3 receptor. Anesth. Analg. 107, 353-355 (2008).
31. Rojas C, Thomas AG, Alt J, et al.: Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol. 626, 193-199 (2010).
32. Grote T, Hajdenberg J, Cartmell AD, et al.: Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomiting after emetogenic chemotherapy. J. Support. Oncol. 4, 403-408 (2006).
33. Shah A, DeGroot T, Apseloff G: Pharmacokinetic evaluation and safety profile of a 15 min versus 30 second infusion of palonosetron in healthy subjects. J. Clin. Pharmacol. 46, 1139-1145 (2006).
34. Stoltz R, Cyong J, Shah A, Parisi S: Pharmacokinetic and safety evaluation of palonosetron, a 5HT3 receptor antagonist, in U.S. and Japanese healthy subjects. J. Clin. Pharmacol. 44, 520-531 (2004).
35. Aapro MS, Macciocchi A, Gridelli C: Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients. J. Support. Oncol. 3, 369-374 (2005).
36. Hajdenberg J, Grote T, Yee L, et al.: Infusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomiting. J. Support. Oncol. 4, 467-471 (2006).
37. Navari RM, Einhorn LH, Loehrer PJ, et al.: A Phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting. Support. Care Cancer 15, 1285-1291 (2007).
38. Navari RM, Einhorn LH, Loehrer PJ, et al.: A Phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support. Care Cancer 13, 529-534 (2005).
39. Cleeland CS, Mendoza TR, Wang, XS, et al.: Assessing symptom distressing cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89, 1634-1646 (2000).
40. Rzepecki P, Plelichowski W, Oborska S, et al.: Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before hematopoietic stem cell transplantation - single center experience. Transplantation Proc. 41(8), 3247-3249 (2009).
41. Einhorn LH, Brames MJ, Dreicer R, et al.: Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support. Care Cancer 15, 1293-1300 (2007).
42. Navari RM: Prevention of emesis from multiple-day chemotherapy regimens. J. Natl Compr. Canc. Netw. 5, 51-59 (2007).
43. Musso M, Scalone R, Bonanno V, et al.: Palonosetron and dexamethasone for the Prevention of acute and delayed nausea and vomiting in patients receiving multi-day chemotherapy. Support. Care Cancer 17, 205-209 (2009).
44. Bissoli F, McGiuggan M, Bertazzoli M: Post-marketing experience of palonosetron confirms a favorable benefit/risk profile. Support. Care Cancer 13(413), A04 (2005).
45. Hajdenberg J: Safety profile of palonosetron, a pharmacologically distinct 5-HT3 receptor antagonist recently approved for acute and delayed chemotherapy induced nausea. Blood 102, 510B (2003) (Abstract 5770).
46. Morganroth J, Parisi S, Moresino C, et al.: High dose palonosetron does not alter parameters including QTC interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron versus moxifloxacin or placebo. Eur. J. Cancer Supple. 5(4), 158 (2007) (Abstract 1156).
47. Raftopoulas H, Bria E, Gralla R, et al.: Is there a preferred dose of palonosetron? Results of an abstracted data meta-analysis of all eight randomized double-blind studies and the impact on guideline considerations. J. Clin. Oncol. 27, 15S (2009) (Abstract 9636).
48. ASCO patient guide: preventing nausea and vomiting caused by cancer treatment (2006) www.plwc.org (Accessed August 2009)
49. The NCCN clinical practice guidelines in oncology (2009) www.nccn.org (Accessed August 2009)
50. Multinational Association of Supportive Care in Cancer antiemetic guidelines (2009) www.mascc.org (Accessed August 2009)